In terms of the mevalonate pathway in TP53-mutant AML cells, we investigated the effect of the competitive HMG-CoA reductase (HMGCR; 3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitor simvastatin, which blocks the rate-limiting step of the mevalonate pathway. The gene discussed is HMGCR; the disease is acute myeloid leukemia.